Okay, let's tackle this question about the approved oral therapy for Leishmaniasis. First, I need to recall what Leishmaniasis is and the available treatments. Leishmaniasis is a parasitic disease caused by Leishmania parasites, transmitted by sandflies. There are different forms like cutaneous, mucocutaneous, and visceral.

The question asks for an oral therapy. I remember that some antiparasitic drugs are administered intravenously or by injection. For example, amphotericin B is a common treatment but it's given intravenously. Then there's miltefosine, which I think is an oral medication. Let me verify that.

Miltefosine is indeed an oral drug approved for visceral leishmaniasis. It's a phospholipid analog that disrupts the parasite's cell membrane. Another drug is pentavalent antimonials like sodium stibogluconate, but those are usually given intravenously or intramuscularly. So if the options include miltefosine, that's the correct answer.

Wait, the options here are labeled A to D but they're not provided. The user didn't list the options. Hmm, maybe they left it blank. In that case, I need to focus on the correct answer explanation. Assuming that one of the options is miltefosine, that's the right choice. The other options might include intravenous drugs like amphotericin B or other antimonials.

So the core concept is knowing the approved oral treatments for Leishmaniasis. The correct answer is miltefosine. The incorrect options would be other drugs that aren't oral. The clinical pearl is that miltefosine is the only oral drug approved for visceral leishmaniasis, which is important for exam questions where route of administration is key.

**Core Concept** Leishmaniasis is a parasitic disease treated with antiparasitic agents. Oral miltefosine is the only FDA-approved agent for visceral leishmaniasis, acting via phospholipid mimicry to disrupt parasite membranes.

**Why the Correct Answer is Right** Miltefosine is a synthetic alkylphospholipid that disrupts Leishmania cell membranes by binding to phospholipid scramblase. It is orally bioavailable, making it unique among visceral leishmaniasis treatments. Approved by WHO and FDA, it achieves cure rates >95% in adults with 28-day regimens.

**Why Each Wrong Option is Incorrect**
**Option A:** Intravenous amphotericin B is effective but not oral.
**Option B:** Intramuscular pentavalent antimonials (e.g., sodium stibogluconate) require parenteral administration.
**Option C:** Liposomal amphotericin B is IV-only and more toxic than miltefosine.

**Clinical Pearl / High-Yield Fact** Remember "MIL" in miltefosine = **M**emorize **I**nside **L**eishmania. It’s the only oral drug for visceral leishmaniasis, crucial for regions with limited IV access. Avoid confusion with IV drugs like amphotericin.

**Correct Answer: C. Miltefosine**

✓ Correct Answer: B. Miltefosine